Oppenheimer analyst Leah Rush Cann initiated shares of CTI BioPharma with an Outperform rating and $5 price target. In a research note to investors, the analyst said she believes that the primary driver of value for the late-stage clinical biotechnology company is pacritinib, its compound for treatment of patients with myelofibrosis, and that since CTI BioPharma is currently dependent on pre-commercial products and is not yet profitable, she is focusing primarily on potential future revenue to value it. She expects CTI to introduce its first to products in the U.S. over the next several years, and sees total revenue growing to $467M in 2024.